SCHEMBL342322

SCHEMBL342322

Cc1cccc2c1NCCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 1/20 0.49
HTR5A P47898 1/20 0.40
ALOX12 P18054 2/20 0.38
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
PARP1 P09874 2/20 0.37
PARP10 Q53GL7 1/20 0.37
PARP11 Q9NR21 1/20 0.37
LMNA P02545 1/20 0.37
NR4A1 P22736 1/20 0.37
HTT P42858 1/20 0.37
NUDT1 P36639 1/20 0.36
HTR1D P28221 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36
TSHR P16473 1/20 0.36
BCL2L1 Q07817 1/20 0.35
BAD Q92934 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15946718 0.94 SRC (0.44) SRCHTR5AALOX12KDM4EALDH1A1
SCHEMBL1870062 0.88 PARP10 (0.43) SRCHTR5AALDH1A1MAPTPARP1
SCHEMBL10912802 0.77 SRC (0.46) SRCKDM4EALDH1A1MAPTPARP1
SCHEMBL15366916 0.77 SRC (0.43) SRCMAPTPARP1PARP10PARP11
SCHEMBL17969105 0.76 SRC (0.49) SRCKDM4EMAPTPARP1TSHR
SCHEMBL1082367 0.76 SRC (0.49) SRCKDM4EALDH1A1HPGDMAPT
SCHEMBL6359546 0.76 SRC (0.53) SRCKDM4EMAPTPARP1PARP10
SCHEMBL5759503 0.76 SRC (0.49) SRCHTR5AALOX12KDM4EALDH1A1
SCHEMBL3744568 0.76 SRC (0.38) SRCALOX12KDM4EALDH1A1HPGD
SCHEMBL6796232 0.76 SRC (0.49) SRCKDM4EPARP10PARP11TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119931978-A Application of monoamine oxidase as catalyst in preparation of quinoline nitrogen heterocyclic compound 河北工业大学 2025-05-06 CN claimed
CN-119702019-A Catalyst for catalyzing selective hydrogenation of quinoline and preparation method thereof 湘潭大学 2025-03-28 CN claimed
CN-109529907-B Nitrogen-doped carbon material supported cobalt catalyst, preparation method thereof and application thereof in catalytic oxidation of N-heterocyclic compound 中南民族大学 2021-10-15 CN claimed
CN-109529907-A A kind of nitrogen-doped carbon material load cobalt catalyst and preparation method thereof and the application in N- heterocyclic compound catalysis oxidation 中南民族大学 2019-03-29 CN claimed
CN-107141252-A A kind of method that hydrotalcite-like materials are catalyzed nitrogen-containing heterocycle compound oxidative dehydrogenation 常州大学 2017-09-08 CN claimed
US-7101869-B2 2,4-diaminopyrimidine compounds useful as immunosuppressants PFIZER INC. (US) 2006-09-05 US claimed
EP-1242403-B1 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS PFIZER PROD INC (US) 2006-01-04 EP claimed
US-20030191307-A1 2,4-Diaminopyrimidine compounds useful as immunosuppressants BLUMENKOPF TODD A (US) 2003-10-09 US claimed
EP-4580621-A2 T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS The Broad Institute, Inc. (US) 2025-07-09 EP disclosed
CN-120091815-A T-type voltage-gated calcium channel enhancer 广泛研究所股份有限公司 2025-06-03 CN disclosed
CN-119931978-A Application of monoamine oxidase as catalyst in preparation of quinoline nitrogen heterocyclic compound 河北工业大学 2025-05-06 CN disclosed
CN-119702019-A Catalyst for catalyzing selective hydrogenation of quinoline and preparation method thereof 湘潭大学 2025-03-28 CN disclosed
CN-115448888-B Preparation method of phenazine compound 华南理工大学 2024-03-12 CN disclosed
WO-2024050312-A2 T-TYPE VOLTAGE-GATED CALCIUM CHANNEL POTENTIATORS THE BROAD INSTITUTE, INC. (US) 2024-03-07 WO disclosed
EP-1242403-A1 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS Pfizer Products Inc. (US) 2002-09-25 EP disclosed
WO-2001040215-A1 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS PFIZER PRODUCTS INC. (US) 2001-06-07 WO disclosed
EP-0428351-B1 Synthesis of quinoline and substituted quinoline copolymers EXXON RESEARCH ENGINEERING CO (US) 1994-12-21 EP disclosed
EP-0428351-A2 Synthesis of quinoline and substituted quinoline copolymers EXXON RESEARCH AND ENGINEERING COMPANY (US) 1991-05-22 EP disclosed
EP-0399278-A2 Heterocyclic amidine derivatives BASF Aktiengesellschaft (DE) 1990-11-28 EP disclosed
EP-0173208-A1 Tetrahydroquinolin-1-yl-carbonyl-imidazole derivatives NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1986-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191307-A1 2,4-Diaminopyrimidine compounds useful as immunosuppressants CCR1, AOC1, NOD1 SRC 3262/4885HTR5A 2812/4885ALOX12 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.